Algeta ASA
Industry
- Biotechnology
- Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Latest on Algeta ASA
Four months after the failure of its lung cancer candidate, Norway’s BerGenBio has chosen to merge with compatriot Oncoinvent and enter the radiopharmaceuticals space. The Bergen-headquartered biotech
For many years, the toxicity associated with the first antibody-drug conjugates (ADCs) kept them away from all but the last lines of treatment for a few hematological cancers. But Gilead Sciences, In
With a number of high-profile exits under its belt, Abingworth has been able to expand its own investor base and raise $315m for ABV VII. The new vehicle is the VC’s 12th fund and means that Abingwort
Although some investors are disappointed by the lack of a straightforward buyout, market analysts agree that Loxo Oncology Inc. achieved victory in multiple ways under an agreement with Bayer AG